Products and withdrawal from the market Sibutramine was approved in 1999 and was commercially available in many countries in 10- and 15-mg capsule form (Reductil, Abbott AG). On March 29, 2010, Abbott AG, in consultation with Swissmedic, informed the public that the marketing authorization had been suspended. Since then, sibutramine may no longer be prescribed … Sibutramine
Effects Antiadiposita differ in their effects. They inhibit appetite or increase satiety, reduce the absorption of food components in the intestine or promote their utilization, increase energy metabolism and degrading metabolic processes. The ideal slimming agent would enable rapid, high and stable weight loss and at the same time be very well tolerated and applicable … Slimming Products
Products Lipid-lowering agents are mainly sold as tablets and capsules as monopreparations and combination preparations. Some other dosage forms exist, such as granules and injectables. Statins have established themselves as the most important group at present. Structure and properties The chemical structure of lipid-lowering agents is inconsistent. However, within the class, groups with comparable structures … Lipid-Lowering Agents
Products Cannabinoid receptor antagonists are no longer on the market in many countries. Rimonabant (Acomplia) was withdrawn from the market in 2008 because it can cause psychiatric disorders, particularly depression. Effects Cannabinoid receptor antagonists have appetite suppressant, lipid-lowering, antidiabetic, analgesic (antiallodynic, antinociceptive), and anti-inflammatory properties. The effects of cannabinoid receptor antagonists are largely opposite to … Cannabinoid Receptor Antagonists
Products Hemp and preparations made from it, such as marijuana, cannabis resin, THC, and cannabis extracts, are generally among the prohibited narcotics in many countries. However, the Federal Office of Public Health may grant exemptions for research, drug development and limited medical use. In 2013, a cannabis oral spray (Sativex) was approved as a medicine … Cannabis
Products Rimonabant was on the market in the form of film-coated tablets (Acomplia, Zimulti) starting in 2006. Because the drug can cause psychiatric disorders such as depression as a side effect, it was withdrawn from the market in 2008. Structure and properties Rimonabant (C22H21Cl3N4O, Mr = 463.8 g/mol) is a chlorinated piperidine and pyrazole carboxamide … Rimonabant
